시장보고서
상품코드
1181117

세계의 천식 및 COPD 치료제 시장(2023-2033년)

Asthma & COPD Therapies Market Report 2023-2033

발행일: | 리서치사: Visiongain Reports Ltd. | 페이지 정보: 영문 248 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 천식 및 COPD 치료제 시장 규모는 2033년까지 7.31%의 CAGR로 확대될 것으로 예측됩니다. 신흥국 시장으로 진출은 앞으로 중요한 의미를 가질 것입니다. 특히 미국과 유럽 시장은 포화 상태에 있으며, 특허 끊김이나 후발 의약품과의 경쟁, 저의료비 등에 따라 성장의 둔화와 쇠퇴를 볼 수 있기 때문에 신흥국 시장으로의 진출은 중요합니다.

세계의 천식 및 COPD 치료제(Asthma & COPD Therapies) 시장에 대해 조사했으며, 시장 개요/제품별·투여 경로별·판매 지점별·지역별 동향/시장 진입 기업 개요 등을 제공하고 있습니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 천식 및 COPD 치료제 시장 소개

제4장 시장 개요

  • 주요 조사 결과
  • 시장 역학
  • 시장 억제 요인
  • 시장 기회
    • 원격 의료
  • Porter’s Five Forces
  • SWOT 분석
  • COVID-19 영향 분석

제5장 천식 및 COPD 치료제 시장 분석, 제품별

  • 주요 조사 결과
  • 제품 부문 : 시장 매력 지수
  • 천식 및 COPD 치료제 시장 규모 추정 및 예측, 제품별
  • 항염증제
  • 기관지 확장제의 단일 치료
  • 배합제

제6장 천식 및 COPD 치료제 시장 분석, 투여 경로별

  • 주요 조사 결과
  • 천식 및 COPD 치료제 시장 규모 추정 및 예측, 투여 경로별
  • 경구
  • 흡입형
  • 기타

제7장 천식 및 COPD 치료제 시장 분석, 판매 지점별

  • 주요 조사 결과
  • POS 부문 : 시장 매력 지수
  • 천식 및 COPD 치료제 시장 규모 추정 및 예측, 판매 지점별
  • 소매 약국
  • 병원 약국
  • 기타

제8장 천식 및 COPD 치료제 시장 분석, 지역별

  • 주요 조사 결과
  • 지역 시장 규모 추정 및 예측

제9장 북미의 천식 및 COPD 치료제 시장 분석

제10장 유럽의 천식 및 COPD 치료제 시장 분석

제11장 아시아태평양 천식 및 COPD 치료제 시장 분석

제12장 남미의 천식 및 COPD 치료제 시장 분석

제13장 중동·아프리카의 천식 및 COPD 치료제 시장 분석

제14장 기업 개요

  • AstraZeneca
  • GSK plc
  • Boehringer Ingelheim
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Mundipharma
  • Cipla Inc.
  • Pulmatrix
  • TFF Pharmaceuticals, Inc.
  • Respiratorius AB
  • Chiesi Farmaceutici SpA
  • Grifols SA
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Transpire Bio
  • Verona Pharma plc

제15장 결론 및 제언

LYJ 23.01.25

The global Asthma & COPD Therapies market is projected to grow at a CAGR of 7.31% by 2033.

“The Asthma & COPD Therapies Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Expansion into Emerging Markets to Offer Lucrative Growth Opportunities

For the overall asthma and COPD market, expansion into the emerging markets will be of high importance in the years to come, in particular as the US and European markets become saturated and experience slow growth or decline due to patent expiry, generic competition and low healthcare budgets. The economic troubles currently being experienced in a number of emerging markets are likely to lift over the next ten years, returning those nations to continued expansion of their healthcare systems and satisfaction of unmet treatment needs. Inhaled drugs will continue to be less affected by patent expiries, as long as the inhaler patents are intact. Advances in inhaler design will continue to be of vital importance to the market.

Nevertheless, the asthma and COPD market have a potential for a number of blockbuster drugs with increasingly segmented sub-groups of patients. The market also benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases, revenues are expected to increase in the years to come. New combination drugs will drive growth. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups. Future success will on long-term planning, to maximise the revenues for existing drugs (life cycle management), to successfully expand into emerging markets and to identify and address unmet needs in the patient population depend on novel and effective therapies.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the asthma & COPD therapies market evolving?
  • What is driving and restraining the asthma & COPD therapies market?
  • How will each asthma & COPD therapies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each asthma & COPD therapies submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading asthma & COPD therapies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the asthma & COPD therapies projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of

asthma & COPD therapies projects taking place now and over the next 10 years?

  • Is there a greater need for product commercialisation to further scale the asthma & COPD therapies market?
  • Where is the asthma & COPD therapies market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the asthma & COPD therapies market today, and over the next 10 years:

  • Our 248-page report provides 107 tables and 130 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the asthma & COPD therapies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Product

  • Anti-inflammatory Drugs
  • Bronchodilators Monotherapy
  • Combination Drugs

Route of Administration

  • Oral
  • Inhaled
  • Others

Point of Sale

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Asthma & COPD Therapies Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grifols S.A.
  • GSK plc
  • Mundipharma
  • Novartis AG
  • Pulmatrix
  • Respiratorius AB
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • TFF Pharmaceuticals, Inc.
  • Transpire Bio
  • Verona Pharma plc
  • Viatris Inc.

Overall world revenue for Asthma & COPD Therapies Market, 2023 to 2033 in terms of value the market will surpass US$47 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Asthma & COPD Therapies Market, 2023 to 2033 report help you?

In summary, our 240+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for Asthma & COPD Therapies Market, 2023 to 2033 Market, with forecasts for Product, Route of Administration, and Point of Sale, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 20 key national markets - See forecasts for the Asthma & COPD Therapies Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 18 of the major companies involved in the Asthma & COPD Therapies Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Asthma & COPD Therapies Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Asthma & COPD Therapies Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Introduction to the COPD and Asthma Therapies Market

  • 3.1 Introduction to the COPD and Asthma Therapies
  • 3.2 The Pharmaceutical Industry: A Very Brief Overview
  • 3.3 What is Asthma?
    • 3.3.1 Trends in Asthma Prevalence
    • 3.3.2 Pathophysiology of Asthma
    • 3.3.3 Symptoms of Asthma
    • 3.3.4 Causes and Triggers for Asthma
    • 3.3.5 Treatment of Asthma
    • 3.3.6 Drug Delivery Methods in Asthma
  • 3.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
    • 3.4.1 Trends in COPD Prevalence
    • 3.4.2 Pathophysiology of COPD
    • 3.4.3 Signs and Symptoms of COPD
    • 3.4.4 Treatment of COPD
    • 3.4.5 Drug Treatments for COPD
    • 3.4.6 Guidelines for COPD Treatment
  • 3.5 Major Drug Classes in the Treatment of Asthma and COPD
    • 3.5.1 Bronchodilators
      • 3.5.1.1 Beta2-Agonists
      • 3.5.1.2 Anticholinergics
    • 3.5.2 Anti-Inflammatory Drugs
      • 3.5.2.1 Corticosteroids
      • 3.5.2.2 Leukotriene Receptor Antagonists
      • 3.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
    • 3.5.3 Combination Drugs

4 Market Overview

  • 4.1 Key Findings
  • 4.2 Market Dynamics
    • 4.2.1 Market Driving Factors
    • 4.2.2 Increasing Prevalence of Respiratory Diseases on Account of Increasing Pollution
    • 4.2.3 Reducing Social Stigma Asthma and COPD
    • 4.2.4 Strong Pipeline for Asthma Drugs
  • 4.3 Market Restraints
  • 4.4 Market Opportunities
    • 4.4.1 Telehealth
  • 4.5 Porter's Five Forces
    • 4.5.1 Bargaining Power of Buyers
    • 4.5.2 Bargaining Power of Suppliers
    • 4.5.3 Threat of Substitutes
    • 4.5.4 Threat of New Entrants
    • 4.5.5 Industry Rivalry
  • 4.6 SWOT Analysis
  • 4.7 COVID-19 Impact Analysis

5 Asthma & COPD Therapies Market Analysis by Product

  • 5.1 Key Findings
  • 5.2 Product Segment: Market Attractiveness Index
  • 5.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Product
  • 5.4 Anti-inflammatory Drugs
    • 5.4.1 Anti-inflammatory Drugs Submarket Forecast by Type, 2023-2033 (US$ bn)
  • 5.5 Bronchodilators Monotherapy
    • 5.5.1 Bronchodilators Monotherapy Submarket Forecast by Type, 2023-2033 (US$ bn)
  • 5.6 Combination Drugs
    • 5.6.1 Combination Drugs Submarket Forecast by Type, 2023-2033 (US$ bn)

6 Asthma & COPD Therapies Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Route of Administration
  • 6.4 Oral
    • 6.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Inhaled
    • 6.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)
  • 6.6 Others
    • 6.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Asthma & COPD Therapies Market Analysis by Point of Sale

  • 7.1 Key Findings
  • 7.2 Point of Sale Segment: Market Attractiveness Index
  • 7.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Point of Sale
  • 7.4 Retail Pharmacies
    • 7.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 7.4.2 Market Share by Region, 2023 & 2033 (%)
  • 7.5 Hospital Pharmacies
    • 7.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 7.5.2 Market Share by Region, 2023 & 2033 (%)
  • 7.6 Others
    • 7.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 7.6.2 Market Share by Region, 2023 & 2033 (%)

8 Asthma & COPD Therapies Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Asthma & COPD Therapies Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Asthma & COPD Therapies Market Attractiveness Index
  • 9.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 9.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 9.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 9.7 U.S. Asthma & COPD Therapies Market Analysis
  • 9.8 Canada Asthma & COPD Therapies Market Analysis

10 Europe Asthma & COPD Therapies Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Asthma & COPD Therapies Market Attractiveness Index
  • 10.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 10.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 10.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 10.7 Germany Asthma & COPD Therapies Market Analysis
  • 10.8 UK Asthma & COPD Therapies Market Analysis
  • 10.9 France Asthma & COPD Therapies Market Analysis
  • 10.10 Italy Asthma & COPD Therapies Market Analysis
  • 10.11 Spain Asthma & COPD Therapies Market Analysis
  • 10.12 Rest of Europe Asthma & COPD Therapies Market Analysis

11 Asia Pacific Asthma & COPD Therapies Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Asthma & COPD Therapies Market Attractiveness Index
  • 11.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 11.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 11.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 11.7 Japan Asthma & COPD Therapies Market Analysis
  • 11.8 China Asthma & COPD Therapies Market Analysis
  • 11.9 India Asthma & COPD Therapies Market Analysis
  • 11.10 Australia Asthma & COPD Therapies Market Analysis
  • 11.11 South Korea Asthma & COPD Therapies Market Analysis
  • 11.12 Rest of Asia Pacific Asthma & COPD Therapies Market Analysis

12 Latin America Asthma & COPD Therapies Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Asthma & COPD Therapies Market Attractiveness Index
  • 12.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 12.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 12.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 12.7 Brazil Asthma & COPD Therapies Market Analysis
  • 12.8 Mexico Asthma & COPD Therapies Market Analysis
  • 12.9 Rest of Latin America Asthma & COPD Therapies Market Analysis

13 MEA Asthma & COPD Therapies Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Asthma & COPD Therapies Market Attractiveness Index
  • 13.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 13.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 13.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 13.7 GCC Asthma & COPD Therapies Market Analysis
  • 13.8 South Africa Asthma & COPD Therapies Market Analysis
  • 13.9 Rest of MEA Asthma & COPD Therapies Market Analysis

14 Company Profiles

  • 14.1 AstraZeneca
    • 14.1.1 Company Snapshot
    • 14.1.2 Company Overview
    • 14.1.3 Financial Analysis
      • 14.1.3.1 Net Revenue, 2015-2021
      • 14.1.3.2 Regional Market Shares, 2021
      • 14.1.3.3 Gross Profit, 2015-2021
      • 14.1.3.4 R&D, 2015-2021
    • 14.1.4 Product Benchmarking
    • 14.1.5 Strategic Outlook
  • 14.2 GSK plc
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Financial Analysis
      • 14.2.3.1 Net Revenue, 2015-2021
      • 14.2.3.2 Regional Market Shares, 2021
      • 14.2.3.3 Gross Profit, 2015-2021
      • 14.2.3.4 R&D, 2015-2021
    • 14.2.4 Product Benchmarking
    • 14.2.5 Strategic Outlook
  • 14.3 Boehringer Ingelheim
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2015-2021
      • 14.3.3.2 Regional Market Shares, 2021
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Teva Pharmaceutical Industries Ltd.
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2015-2021
      • 14.4.3.2 Regional Market Shares, 2021
      • 14.4.3.3 Gross Profit, 2015-2021
      • 14.4.3.4 R&D, 2015-2021
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Viatris Inc.
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2015-2021
      • 14.5.3.2 Gross Profit, 2015-2021
      • 14.5.3.3 R&D, 2015-2021
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 F. Hoffmann-La Roche Ltd.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2015-2021
      • 14.6.3.2 Gross Profit, 2015-2021
      • 14.6.3.3 R&D, 2015-2021
    • 14.6.4 Product Benchmarking
  • 14.7 Novartis AG
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2015-2021
      • 14.7.3.2 Regional Market Shares, 2021
      • 14.7.3.3 Gross Profit, 2015-2021
      • 14.7.3.4 R&D, 2015-2021
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Mundipharma
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Product Benchmarking
  • 14.9 Cipla Inc.
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2015-2021
      • 14.9.3.2 Regional Market Shares, 2021
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 Pulmatrix
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Product Benchmarking
    • 14.10.4 Strategic Outlook
  • 14.11 TFF Pharmaceuticals, Inc.
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Product Benchmarking
    • 14.11.4 Strategic Outlook
  • 14.12 Respiratorius AB
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Product Benchmarking
  • 14.13 Chiesi Farmaceutici S.p.A.
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Product Benchmarking
  • 14.14 Grifols S.A.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue, 2015-2021
      • 14.14.3.2 Regional Market Shares, 2021
      • 14.14.3.3 Gross Profit, 2015-2021
      • 14.14.3.4 R&D, 2015-2021
    • 14.14.4 Product Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Sanofi SA
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2015-2021
      • 14.15.3.2 Regional Market Shares, 2021
      • 14.15.3.3 Gross Profit, 2015-2021
      • 14.15.3.4 R&D, 2015-2021
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Sunovion Pharmaceuticals Inc.
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Product Benchmarking
  • 14.17 Transpire Bio
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Product Benchmarking
  • 14.18 Verona Pharma plc
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Product Benchmarking
    • 14.18.4 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from
  • 15.2 Recommendations for Market Players
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제